• Mashup Score: 4
    Cancer vaccines: the next immunotherapy frontier - Nature Cancer - 2 year(s) ago

    Brody and colleagues discuss the current status and potential of cancer vaccines, highlighting challenges and opportunities to advance promising candidates to the clinic.

    Source: Nature
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NatureCancer
      NatureCancer

      💫DON’T MISS this Review on #CancerVaccines as part of our #SeriesCancerImmunotherapy – a beautiful overview by @joshuabrodyMD @matthew_j_lin @DrIgMelero & Co. Read it👇 https://t.co/SrjbpUUIv4 https://t.co/VCwLLybuLS Series 👇 https://t.co/0PtRlScYXv https://t.co/MtsTgFw9G5

  • Mashup Score: 6
    Series on Cancer Immunotherapy - 2 year(s) ago

    We present our Series on Cancer immunotherapy comprising commissioned Reviews, Perspectives and opinion pieces on the latest advances in the evolving palette …

    Source: Nature
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NatureCancer
      NatureCancer

      ⭐️ICYMI - read the Review “Engineering-enhanced CAR T cells for improved cancer therapy” by Jan Joseph Melenhorst @ImmunoTx & Co as part of our #SeriesCancerImmunotherapy #CARTell (https://t.co/0PtRlScYXv). Find it here 👇 https://t.co/9mq3DydmRO https://t.co/DUpiJtYsex

  • Mashup Score: 4
    Series on Cancer Immunotherapy - 2 year(s) ago

    We present our Series on Cancer immunotherapy comprising commissioned Reviews, Perspectives and opinion pieces on the latest advances in the evolving palette …

    Source: Nature
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NatureCancer
      NatureCancer

      💫As part of our #SeriesCancerImmunotherapy (https://t.co/0PtRlScYXv) we would like to highlight a beautiful review - “The current landscape of immunotherapy for pediatric brain tumors” by #EugeneHwang & co. Find it here 👇 https://t.co/c83NyVjFMU https://t.co/Ls7qhpFH6a

  • Mashup Score: 1
    Series on Cancer Immunotherapy - 2 year(s) ago

    We present our Series on Cancer immunotherapy comprising commissioned Reviews, Perspectives and opinion pieces on the latest advances in the evolving palette …

    Source: Nature
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NatureCancer
      NatureCancer

      💫As part of our #SeriesCancerImmunotherapy (https://t.co/0PtRlScYXv) we would like to highlight “Bystander T cells in cancer immunology and therapy” by @StefanieLMeier @Satpathology #DanielKWells #Immunotherapy Read here👇 https://t.co/wTB4bXrXRA https://t.co/4KUEBQC0Wt

  • Mashup Score: 0
    The status of tumor mutational burden and immunotherapy - Nature Cancer - 2 year(s) ago

    Tumor mutational burden (TMB) has received significant attention within ongoing pursuits of biomarkers of response to immune checkpoint inhibitors, and notably received FDA approval as a companion diagnostic biomarker for pembrolizumab. Here, four experts discuss the utility, challenges, and open questions surrounding TMB in the context of cancer immunotherapy.

    Source: Nature
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NatureCancer
      NatureCancer

      Another ⭐️highlight⭐️ from our #SeriesCancerImmunotherapy – “The status of tumor mutational burden and immunotherapy” – a viewpoint by #ValsamoAnagnostou, @Albert0Bardelli, @GeneCollector and @SamraTurajlic! Read it here: https://t.co/OZjwkHCqpL https://t.co/crmos8u6uF